MedTrace Logo

UVA1 Light for Treatment of Scleroderma and Similar Conditions

NCT00476801 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2015-07-10

No results posted yet for this study

Summary

The purpose of this investigation is to evaluate the effectiveness of an investigational device which is similar in appearance to a "tanning bed" but which emits ultraviolet irradiation of a specific wavelength known as UVA1. This device has not been approved by the FDA for general use in this country, as yet, but it has been used quite successfully in Europe for several years in treating such conditions as scleroderma, keloids, and other fibrosing conditions of the skin. Your participation in this study may yield important information regarding the safety and effectiveness of this form of light therapy for the treatment of these skin conditions which, at present, are difficult to treat.

Conditions

  • Scleroderma
  • Keloids
  • Other Fibrosing Conditions

Interventions

DEVICE

German manufactured UVA1 light emitting device

The UVA1 dose will be up to 130 J/cm2.

Sponsors & Collaborators

Principal Investigators

  • Sewon Kang, MD · University of Michigan hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
10 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31
Primary Completion
2004-02-29
Completion
2004-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00476801 on ClinicalTrials.gov